Status:
UNKNOWN
Efficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, or With MRD+ (FRENCH-CYTO)
Lead Sponsor:
Group for Research in Adult Acute Lymphoblastic Leukemia
Collaborating Sponsors:
Amgen
Conditions:
Acute Lymphoblastic Leukemia, in Relapse
Acute Lymphoblastic Leukemia With Failed Remission
Eligibility:
All Genders
18+ years
Brief Summary
The outcome of young adults (18-60 years) with ALL has been dramatically improved by the use of pediatric-inspired trials. About 60% of these young adult patients will be cured at 5 years. In this con...
Detailed Description
To evaluate the efficacy of blinatumomab given in the French Compassionate Use Program, in term of overall survival in both R/R (first cohort) and MRD positive (second cohort) patients. To evaluate t...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patient with Philadelphia-negative or positive (Ph+) ALL in relapse, refractory to salvage therapy, or with MRD positive ALL that received blinatumomab in the French ATU program.,
- Patient treated in the GRAALL network,
- Patient who does'nt object to participate in the study
- Exclusion Criteria :
- \- none
Exclusion
Key Trial Info
Start Date :
July 16 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 30 2019
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT03751072
Start Date
July 16 2018
End Date
January 30 2019
Last Update
November 23 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CABANNES-HAMY Aurélie
Paris, France, 75010